Loading patent…
AssigneeNovartis AG
InventorsEric Billy, Antoine De Weck, Javad Golji, Gregory Hoffman, Francesco Hofmann, Audrey Kauffmann, Konstantinos John Mavrakis, Earl Robert McDonald, III, William Sellers, Tobias Schmelzle, Frank Peter Stegmeier, Michael Ray Schlabach, Jr.
Estimating the term…
The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.
A method of treating microsatellite instable (MSI+) cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a WRN inhibitor wherein the cancer is selected from a group consisting of hematopoietic cancer, skin cancer, lung cancer, colorectal cancer, stomach cancer, thyroid cancer, melanoma, uveal melanoma, pancreatic cancer, endometrial cancer, Ewing's sarcoma, breast cancer, CNS cancer, kidney cancer, bladder cancer, esophageal cancer, upper aerodigestive cancer, neuroblastoma, ovarian cancer, liver cancer, and colon cancer.
Dependencies are inferred from the claim text.